Another Major Drug Approval for Regeneron
Congratulations to BCW member Regeneron on the approval of an important new drug to help patients with rheumatoid arthritis. The U.S. Food and Drug Administration has approved the human antibody drug sarilumab, developed by Regeneron Pharmaceuticals Inc. in Westchester and its French pharmaceutical partner Sanofi and trademarked as Kevzara, to treat adult patients with moderately to severely active rheumatoid arthritis.
The FDA approval came less than two months after the federal agency approved Regeneron’s and Sanofi’s human antibody dupilumab, marketed as Dupixent, as the first biologic medicine used to treat the debilitating itching and widespread rashes afflicting adults with moderate to severe cases of atopic dermatitis.
Similar News Items
On Thursday, lohud.com published an editorial by BCW Executive Vice President and COO John Ravitz, who argues that a proposed bill requiring prevailing wages on private construction projects in New York will severely hinder Westchester’s development, exacerbate the housing crisis, and lead to significant job and economic losses. Click here to read the editorial.
In what is an unprecedented Westchester County public-private partnership, BCW Member MacQuesten Development broke ground on Crescent Manor, a new construction project of 73 affordable senior housing which includes one live-in Superintendent’s unit. The building has been designed for seniors to age in place. It will be a low-rise elevator building, with 79 on-site parking […]
The City of Yonkers is launching a multi-platform advertising campaign aimed at positioning Yonkers as “Hollywood on Hudson,” the largest film and TV production hub in the Northeast. The ad campaign, which debuted Wednesday, includes TV commercials, bus exteriors, billboards, MTA car cards on trains, paid social and organic social. The goal is to position […]
Become A Member
Join the county’s largest and most influential business organization today.
JOIN NOW!
Leave a Comment
You must be logged in to post a comment.